VAERS Reports CN5318

VAERS 1066940

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge CN5318

schwer

Staat: FL
Alter: 73,0
Geschlecht: F
Eingang: 02.03.2021
Impfdatum: 02.02.2021
Beginn: 18.02.2021
Tage bis Beginn: 16,0
Dosis: 2
Route/Site: SYR / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Bell's palsy

Symptomtext

Bells Palsy

Weitere VAERSDATA-Felder

Praegender Schweregrund: Bell's palsy
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: None
Vorgeschichte: High blood pressure
Andere Medikamente: Levothyroxine .075 MG Benazepril/HCTZ 20/12.5 MG Adopt eye drops Latanaprost eye drops Vitamin D Vitamin C
Allergien: None
Vorherige Impfungen: Shingrix #1 Age 73 11/19/20

VAERS 1537782

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge CN5318

moderat

Staat: HI
Alter: 23,0
Geschlecht: M
Eingang: 09.08.2021
Impfdatum: 27.01.2021
Beginn: 29.01.2021
Tage bis Beginn: 2,0
Dosis: 1
Route/Site: SYR / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: ja Erholt: ja

Alanine aminotransferase normal Anion gap normal Aspartate aminotransferase normal Basophil count normal Basophil percentage increased Blood albumin normal Blood alkaline phosphatase normal Blood bicarbonate normal Blood bilirubin normal Blood calcium normal Blood chloride normal Blood cholesterol normal Blood creatinine normal Blood glucose normal Blood potassium normal Blood sodium normal Blood thyroid stimulating hormone normal Blood triglycerides decreased

Symptomtext

At approximately 9PM, 2 days after recieving my vaccine, I started experiencing muscle soreness in the arms and shoulders. The soreness worsened so I decided to lay down and sleep it off. While laying in bed the pain spread to my neck, jaw and teeth. After about 3 hours most of the pain subsided but was left with chest, neck, and left arm pain. I checked my heart rate on my smart watch and it was 144 BPM. It was at this point I drove myself to the emergency room and was admitted into the hospital. Patient Discharge Summary: The patient is a 23 year old male who presented to the emergency department with four hours of chest pain after receiving COVID-19 vaccinationapproximately 48 hours prior to that. He was found to have tachycardia and STdepression of the lateral leads. Tachycardia and chest pain resolved withlabetalol and the patient was admitted for observation on telemetry. Over 48 hours on telemetry, he remained in normal sinus rhythm with heart ratesranging 60-100bpm. He did not complain of any additional chest pain whileadmitted to the hospital. He underwent daily electrocardiograms that revealedsome signs suggestive of pericarditis, however he remained without symptoms toindicate need for treatment and resolved on ECG the morning of discharge. Heremained without chest pain or palpitations.Troponins (cardiac enzymes) collected on admission and on repeat were normal. Heunderwent a coronary artery calcium scoring, which revealed a score of 0 with lowrisk of acute coronary syndrome. Finally his transthoracic cardiac echocardiogramrevealed normal cardiac function. Overall workup suggestive of a post-viral picture in setting of recent COVID vaccine.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Chest pain
Hospital-Tage: 4,0
Labordaten: *Labs listed on continuation page I had an MRI and cardiac stress test the following week but do not personally have the results. Labs: January 30, 2021 GFR Black SERUM 113.8 mL/min Lipids+Glucose Site / Specimen 30 Jan 2021 0545 <o> Units Ref Range Cholesterol SERUM 140 mg/dL (200) Triglyceride SERUM 37 mg/dL (150) HDL cholesterol SERUM 68 mg/dL LDL Cholesterol Direct SERUM 60 mg/dL Glucose SERUM 108 (H) mg/dL (70-105) Hemoglobin Alc Panel Site / Specimen 30 Jan 2021 0545 <o> Units Ref Range Hemoglobin Alc BLOOD 4.9 % (5.6) Estimated Average Glucose BLOOD 94 mg/dL CBC W/Auto Diff Site / Specimen 30 Jan 2021 0545 <O> Units Ref Range MCV BLOOD 90.6 fL (80-100) MCH BLOOD 29.5 pg (26-34) MCHC BLOOD 32.5 g/dL (32-36) WBC BLOOD 13.0 (H) x10 (9)/L (3.9-10.6) MPV BLOOD 10.7 fL (9.4-12.4) RBC BLOOD 4.68 x10 (12)/L (4.5-5.9) Hemoglobin BLOOD 13.8 g/dL (13.3-17.7) Hematocrit BLOOD 42.4 % (40.0-53.1) Platelets BLOOD 183 x10 (9)/L (150-440) Lymphocytes BLOOD 14.3 (L) % (22-44) Monocytes BLOOD 9.6% (0-10) ABS Lymphocytes BLOOD 1.86 x10 (3) /mcL (1.0-4.8) ABS Monocytes BLOOD 1.24 (H) x10 (3) /mcl (0-0.8) ABS Neutrophils BLOOD 9.78 (H) x10 (3)/mcL (1.0-4.8) RDW CV BLOOD 12.6 % (11.5-14.5) Granulocytes BLOOD 75.3 (H) % (42.2-75.2) ABS Eosinophils BLOOD 0.01 x10 (3) /mcl (0-.45) ABS Basophils BLOOD 0.03 x10 (3) /mcL (0-20) Eosinophils BLOOD 0.1 % (0-5) Basophils BLOOD 0.2% (0-3) Troponin I Cardiac Site / Specimen 30 Jan 2021 0430 Units Ref Range Troponin I Cardiac PLASMA <0.010 ng/mL (0-.034) Drug Screen Urine Site / Specimen 30 Jan 2021 0350 Units Ref Range Tetrahydrocannabinol URINE NEGATIVE (NEGATIVE) Benzodiazepines URINE NEGATIVE (NEGATIVE) Amphetamines URINE NEGATIVE (NEGATIVE) Cocaine URINE NEGATIVE (NEGATIVE) Opiates URINE NEGATIVE (NEGATIVE) SARS-CoV-2+Influenza A/B Virus+Respiratory Syncytial Virus PCR Site / Specimen Jan 2021 0217 Units Ref Range SARS-CoV-2 PCR NASOPHARYNX NEGATIVE Influenza A PCR NASOPHARYNX NEGATIVE Influenza B PCR NASOPHARYNX NEGATIVE Resp Syncytial Virus PCR NASOPHARYNX NEGATIVE Fibrin D-Dimer Site / Specimen 30 Jan 2021 0200 Units Ref Range Fibrin D-Dimer FEU PLASMA 0.34 mcg/mL FEU (0-0.50) Troponin I Cardiac Site / Specimen 30 Jan 2021 0138 Units Ref Range Troponin I Cardiac PLASMA 0.015 ng/mL (0-.034) Comprehensive Metabolic Panel Site / Specimen 30 Jan 2021 0138 Units Ref Range Glucose SERUM 110 (H) mg/dL (70-105) Creatinine SERUM 1.13 mg/dL (.57-1.25) Urea Nitrogen SERUM 12 mg/dL (7-23) Sodium SERUM 140 mmol/L (136-145) Potassium SERUM 3.6 (L) mmol/L (3.7-5.3) Chloride SERUM 105 mmol/L (98-107) Bicarbonate SERUM 20 (L) mmol/L (22-29) Anion Gap SERUM 15 mmol/L (8-16) Calcium SERUM 9.5 mg/dL (8.4-10.2) Alanine Aminotransferase SERUM 11 U/L (10-55) Albumin SERUM 5.0 g/dL (3.5-5.0) Alkaline Phosphatase SERUM 75 U/L (40-150) Aspartate Aminotransferase SERUM 26 U/L (5-34) Bilirubin SERUM 0.5 mg/dL (0.2-1.2) Protein SERUM 7.8 g/dL (6.4-8.3) GFR Non-Black SERUM 91.1 mL/min GFR Black SERUM 105.3 mL/min Triiodothyronine Site / Specimen 30 Jan 2021 0138 Units Ref Range Triiodothyronine SERUM 0.99 ng/ml (.5-1.6) Thyroxine Free Site / Specimen 30 Jan 2021 0138 Units Ref Range Thyroxine Free SERUM 1.05 ng/dL (.8-1.6) Thyroid Stimulating Hormone Site / Specimen 30 Jan 2021 0138 Units Ref Range Thyrotropin SERUM 5.8829 (H) mIU/mL (.35-5.0) CBC W/Auto Diff Site / Specimen 30 Jan 2021 0138 Units Ref Range MCV BLOOD 91.2 L (80-100) MCH BLOOD 29.6 pg (26-34) MCHC BLOOD 32.5 g/dL (32-36) WBC BLOOD 12.2 (H) x10 (9) /L (3.9-10.6) MPV BLOOD 10.7 FL (9.4-12.4) RBC BLOOD 4.86 x10 (12)/L (4.5-5.9) Hemoglobin BLOOD 14.4 g/dL (13.3-17.7) Hematocrit BLOOD 44.3 % (40.0-53.1) Platelets BLOOD 190 x10 (9)/L (150-440) Lymphocytes BLOOD 30.7 % (22-44) Monocytes BLOOD 11.4 (H) % (0-10) ABS Lymphocytes BLOOD 3.76 x10 (3)/mcL (1.0-4.8) ABS Monocytes BLOOD 1.39 (H) x10 (3) /mcl (0-0.8) ABS Neutrophils BLOOD 6.91 (H) x10 (3)/mcl (1.0-4.8) RDW CV BLOOD 12.5 % (11.5-14.5) Granulocytes BLOOD 56.5 % (42.2-75.2) ABS Eosinophils BLOOD 0.09 X10 (3) /mcl (0-.45) ABS Basophils BLOOD 0.04 x10 (3) /mcL (0-20) Eosinophils BLOOD 0.7 % (0-5) Basophils BLOOD 0.3% (0-3) Discharge Labs and Study Results CBC W/Auto Diff Site / Specimen 31 Jan 2021 0315 ?o> Units Ref Range MCV BLOOD 91.3 fL (80-100) MCH BLOOD 29.5 pg (26-34) MCHC BLOOD 32.3 g/dL (32-36) WBC BLOOD 7.0 x10 (9)/L (3.9-10.6) MPV BLOOD 10.6 fL (9.4-12.4) RBC BLOOD 4.61 x10 (12)/L (4.5-5.9) Hemoglobin BLOOD 13.6 g/dL (13.3-17.7) Hema atocrit BLOOD 42.1 Dlatelets BLOOD 164 x 140.0-53.1) (150-440) Lymphocytes BLOOD 45.4 (H) (22-44) ABS Lymphocytes BLOOD 3.18 x10 (3) /mcL (1.0-4.8) ABS Monocytes BLOOD 0.70 x10 (3) /mcL (0-0.8) ABS Neutrophils BLOOD 2.99 x10 (3) /mcL (1.0-4.8) RDW CV BLOOD 12.7 % (11.5-14.5) Granulocytes BLOOD 42.6 % (42.2-75.2) ABS Eosinophils BLOOD 0.08 x10 (3) /mcL (0-.45) ABS Basophils BLOOD 0.04 x10 (3) /mcl (0-20) Eosinophils BLOOD 1.1 % (0-5) Basophils BLOOD 0.6 % (0-3) (0-10) Comprehensive Metabolic Panel Site / Specimen 30 Jan 2021 0545 co> Units Ref Range Glucose SERUM 108 (H) mg/dL (70-105) Creatinine SERUM 1.06 mg/dL (.57-1.25) Urea Nitrogen SERUM 10 mg/dL (7-23) Sodium SERUM 138 mmol/L (136-145) Potassium SERUM 4.3 mmol/L (3.7-5.3) Chloride SERUM 105 mmol/L (98-107) Bicarbonate SERUM 24 mmol/L (22-29) Anion Gap SERUM 9 mmol/L (8-16) Calcium SERUM 9.4 mg/dL (8.4-10.2) Alanine Aminotransferase SERUM 10 U/L (10-55) Albumin SERUM 4.8 g/dL (3.5-5.0) Alkaline Phosphatase SERUM 67 U/L (40-150) Aspartate Aminotransferase SERUM 24 U/L (5-34) Bilirubin SERUM 0.5 mg/dL (0.2-1.2) Protein SERUM 7.4 g/dL (6.4-8.3) GPR Non-Black SERUM 98.4 mL/min
Aktuelle Erkrankungen: None
Vorgeschichte: None
Andere Medikamente: None
Allergien: None
Vorherige Impfungen: -

VAERS 1792021

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge CN5318

mild

Staat: NY
Alter: 74,0
Geschlecht: F
Eingang: 16.10.2021
Impfdatum: 26.02.2021
Beginn: 01.03.2021
Tage bis Beginn: 3,0
Dosis: 1
Route/Site: - / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Vaccination site rash

Symptomtext

Severe, elevated rash at vaccination site; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: CN5318) via an unspecified route of administration in the left arm on 26Feb2021 at 14:15 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes, high blood pressure and slow thyroid. The patient has no known allergies to medications, food, or other products (also reported as not that known of). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included metformin (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID), enalapril maleate (MANUFACTURER UNKNOWN) and rosuvastatin calcium (ROSUVAST); all for unknown indications from unknown date and unknown if ongoing. On 01Mar2021 at 09:00, the patient experienced severe, elevated rash presented 3 days after vaccination on her left arm at vaccination site. It was also reported that, as of 12Mar2021 (14 days after shot) it was still there. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe, elevated rash at vaccination site was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Vaccination site rash
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: Medical History/Concurrent Conditions: Blood pressure high (High BP); Diabetes (Type 2 diabetes); Hypothyroidism (Slow thyroid)
Andere Medikamente: METFORMIN; SYNTHROID; ENALAPRIL MALEATE; ROSUVAST
Allergien: -
Vorherige Impfungen: -

VAERS 1163036

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge Cn5318

mild

Staat: CT
Alter: 66,0
Geschlecht: F
Eingang: 03.04.2021
Impfdatum: 17.02.2021
Beginn: 19.02.2021
Tage bis Beginn: 2,0
Dosis: 1
Route/Site: SYR / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja

Headache

Symptomtext

I had minor headaches 5 out of 8 days. At first I thought it was just a headache but after repeat headaches , which would be unusual for me, I realized it was probably the shot. Not major pounding headaches, more like eye strain annoying type headaches. Aspirin didn?t provide much relief. Motrin was better.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Headache
Hospital-Tage: -
Labordaten: None
Aktuelle Erkrankungen: None
Vorgeschichte: None
Andere Medikamente: None
Allergien: None
Vorherige Impfungen: -

VAERS 1068224

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge CN5318

mild

Staat: FL
Alter: 71,0
Geschlecht: F
Eingang: 03.03.2021
Impfdatum: 29.01.2021
Beginn: 29.01.2021
Tage bis Beginn: 0,0
Dosis: 2
Route/Site: - / RA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Asthenia Fatigue Headache Malaise Myalgia Nausea

Symptomtext

Nauseous; Weak; Really unwell; Tired; Muscle aches; Headache; This is a spontaneous report from a contactable consumer. A 71-year-old female patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) lot number: CN5318, via an unspecified route of administration at right arm on 29Jan2021 09:00 at a single dose for COVID-19 immunisation. Medical history was not reported. Historical vaccine included first dose of BNT162B2 on an unspecified date. There were no concomitant medications. On 29Jan2021, at 7 pm, the patient was nauseous and weak. At 9 pm, the patient was really unwell, tired, headache, muscle aches and nausea. She slept all Friday night, all day Saturday. Late around Sunday was finally able to get out of bed. Asked if she should see a doctor. The patient was still nauseous and weak. The outcome of the events nausea and weak was not recovered. The outcome of other events was unknown.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Fatigue
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 1332682

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge CN5318

gering

Staat: FL
Alter: 80,0
Geschlecht: F
Eingang: 20.05.2021
Impfdatum: 26.01.2021
Beginn: 12.04.2021
Tage bis Beginn: 76,0
Dosis: 2
Route/Site: - / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Cytogenetic analysis Cytogenetic analysis abnormal

Symptomtext

BCR-ABL test jumped very high; This is a spontaneous report received from a contactable consumer (patient) via medical information and via Pfizer-sponsored program. An 81-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 at the age of 80 years old via an unspecified route of administration, administered in arm left on 26Jan2021 (Batch/Lot Number: CN5318) as 2nd dose, single for COVID-19 immunization and bosutinib (BOSULIF), oral from an unspecified date (Batch/Lot Number: unknown) to an unspecified date at 300 mg, 1x/day for chronic myeloid leukemia. Patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscular, administered in arm right on 05Jan2021 (Batch/Lot Number: EK4176) as 1st dose, single. Medical history included chronic myeloid leukemia. The patient's concomitant medications were not reported. Patient experienced: BCR-ABL (Philadelphia chromosome) test jumped very high on 12Apr2021 (her results went from 1.9 to 11.8). The event was considered related to the medicinal products. Seriousness criteria reported as serious. Outcome of the event was unknown. She has not had any testing since. Action taken in response to the event for bosutinib was dose not changed.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Cytogenetic analysis
Hospital-Tage: -
Labordaten: Test Name: BCR-ABL; Result Unstructured Data: Test Result:1.9; Test Date: 20210412; Test Name: BCR-ABL; Result Unstructured Data: Test Result:11.8; Comments: her results went from 1.9 to 11.8; Test Date: 20210412; Test Name: BCR-ABL; Result Unstructured Data: Test Result:very high
Aktuelle Erkrankungen: -
Vorgeschichte: Medical History/Concurrent Conditions: Chronic myeloid leukemia
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -